App-Quantinova.ai

Hyperglycemia Disrupts Regional Brain Functional Connectivity and Increases Glutamate Neurotransmitter Levels in Type 1 Diabetes: A Link to the Development of Depression?

Nicolas R Bolo - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 1 diabetes mellitus

N/A

The Impact of Perioperative Hyperglycemia in Patients with and without Diabetes Undergoing Coronary Artery Bypass Surgery

Francisco J Pasquel - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acute renal failure

N/A

Use of an Artificial Pancreas Among Adolescents to Minimize Extreme Hyperglycemia in the Setting of Insulin Omission for Food

Mark Daniel DeBoer - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 1 diabetes mellitus

N/A

Liraglutide Exerts an Anti-Inflammatory Effect

Husam Ghanim - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Liraglutide

Liraglutide As Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus: A Randomized Clinical Trial

Nitesh D Kuhadiya - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 1 diabetes mellitus

Liraglutide

Fitness Impact on Renal Function and Chronic Kidney Disease in Type 2 Diabetics

Shruti Mahendra Gandhi - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Microvascular complications of diabetes 1

N/A

Comparative Effectiveness for Cardiometabolic Outcomes of Roux-En-Y Gastric Bypass with Intensive Diabetes and Weight Management in Obese Type 2 Diabetes

Su Ann Ding - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Coronary Artery Disease

N/A

Changes in Patient-Reported Outcomes up to Two Years after Roux-En-Y Gastric Bypass Vs. Intensive Medical Weight Management in Obese Patients with Type 2 Diabetes Mellitus

Donald C Simonson - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Less Stringent Blood Glucose Target in Medical ICU Patients: Effect on the Frequency of Use of Insulin Infusion, Glycemic Control and Clinical Outcomes

Pritisheel Banga - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Impact of U-500 Insulin on Glycemic Control, Risk of Hypoglycemia, and Mortality in Patients with Extreme Insulin Resistance: The VA Pittsburgh Experience

Michael C. Grimes - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

The Effect of Soy Phytoestrogens on Cardiovascular Risk Markers in Men with Type 2 Diabetes and Subclinical Hypogonadism - a Randomised Double Blind Parallel Study

Thozhukat Sathyapalan - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Improved Activities of Daily Living, Normal Mood and Quality of Life: 4 Years of Treatment Data in a Premenopausal Women with Cushing-s Disease

Daphne T Adelman - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acanthosis Nigricans

Glucocorticoid

Quality Improvement in Inpatient Diabetes Care Decreases Wasteful HbA1c Testing

Lena Shalem - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Success of Educational Interventions on Use of Incretin Agents in the Management of Type 2 Diabetes

Amy Larkin - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Planned Changes in Type 2 Diabetes Management: Effectiveness of CME in Practice

Amy Larkin - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Fuldazin

Exploratory Data Evaluating the Effect of Pasireotide on GH, IGF-1, IGFBP-2, IGFBP-3, HbA1c and Glucose in Patients with Inadequately Controlled Acromegaly Enrolled in a 24-Week Study (PAOLA)

Herbert A Schmid - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hyperglycemia

Lanreotide

Sleep Apnea, Defined By Polysomnography, Is Highly Prevalent in Acromegaly and Is Associated with Several Risk Factors and Complications

Marie Jagot - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Left ventricular hypertrophy

N/A

Therapeutic Effects in Acromegalics According to the Latest Criteria

Yuki Kasamo - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acromegaly

Mecasermin

The Effect of Type 2 Diabetes on Serum GH and IGF-I Levels in Relatively Lean Japanese Patients

Kentaro Suda - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Severe Hyperglycemia As Initial Manifestation in a Patient with Acromegaly and Coexisting Preclinical Cushingxs Disease

Birgit Harbeck - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Pituitary adenomas

hGH

Filters

4759 Abstracts